上皮源性细胞因子及其靶向抗体在哮喘中的研究进展  

Research progress of epithelial-derived cytokines and their targeting antibodies in asthma

作　　者：李佳颖(综述) 王炜(审校)[1] 陈彦(审校)[1] LI Jiaying;WANGWei;CHENYan(Department of Immunology,School of Basic Medical Sciences,Capital Medical University,Beijing 100069,China)

机构地区：[1]首都医科大学基础医学院免疫学系,北京100069

出　　处：《微生物学免疫学进展》2024年第2期86-93,共8页Progress In Microbiology and Immunology

基　　金：国家自然科学基金(81971510)。

摘　　要：哮喘(asthma)是以慢性气道炎症、气道高反应性、气道重塑和可逆性气流受限为基本特征的慢性呼吸系统疾病之一。研究表明,上皮源性细胞因子中的白细胞介素(interleukin, IL)-33、IL-25和胸腺基质淋巴细胞生成素(thymic stromal lymphopoietin, TSLP)在哮喘的发生、发展中起到重要作用。目前,针对上皮源性细胞因子研发的单克隆抗体药物已成为治疗哮喘的新型靶点。现就IL-33、IL-25和TSLP的作用机制及针对这3种细胞因子的靶向单克隆抗体在哮喘治疗中的研究作一概述。Asthma is one of the chronic respiratory diseases characterized by chronic airway inflammation, airway hyperresponsiveness, airway remodeling and reversible airflow obstruction. Studies have shown that interleukin-33(IL-33),interleukin-25(IL-25) and thymic stromal lymphopoietin(TSLP) in epithelial-derived cytokines play an important role in the development of asthma. Therefore, monoclonal drugs targeting epithelial-derived cytokines have become a new hot spot in the treatment of asthma. This review briefly summarizes the role of TSLP and IL-33,IL-25,as well as the progress of research on the treatment of asthma targeting monoclonal antibodies against these three cytokines.

关 键 词：哮喘 胸腺基质淋巴细胞生成素 白细胞介素-33 白细胞介素-25 

分 类 号：R392.8[医药卫生—免疫学]